Plenary Lecture: New Frontiers in HIV Protease Inhibitors
April 11, 1997
The present protease inhibitors, as monotherapies, have various limitations.
A way forward was illustrated with ABT-378. When co-administered with a small dose of ritonavir, the plasma levels of ABT-378 are both high and long lasting. Once or twice daily dosing should keep the drug levels well above those needed to prevent HIV replication throughout the whole day. Simpler drug schedules will help patients from giving the virus chances for replication and gaining resistance.
This article was provided by TheBodyPRO. It is a part of the publication The 10th Annual International Society For Antiviral Research Conference.